Follow the structural difference into a candidate
The capability family includes tetrad, ion and loop geometry; placed ligand poses; topology and shape comparisons; groove-directed substitutions; and chemically represented candidate assembly. The proposed chain connects a target/off-target difference to a substituent direction and a matched molecular series. Formation prediction, binding and functional modulation retain separate evidence requirements.
The design operations
These named operations extend the rG4 investigation. Their maturity varies, and the later design routes do not inherit the evidence for formation prediction.
- Selectivity feasibility · Estimate a model-dependent bound on separating the target from a competing structure.
- Topology and shape · Find structural distinctions to test alongside an energy difference.
- Groove-directed ligand arms · Turn a geometric distinction into a substituent direction for a matched series.
- MM and QM binding tiers · Evaluate placed-atom poses, interaction energies and calibrated estimates; optional QM refinement depends on the required software.
- Potency and selectivity trade-offs · Compare target and off-target behavior and test whether charge explains the apparent selectivity.
- Ligand assembly · Build and verify molecular representations for subsequent synthesis and binding assessment.
- Modality rerouting · Consider another architecture or intervention when the initial end-stacking proposal fails.
What has been tested
Formation and selected structural-localization studies have computational results. The later design stages are at different levels of development and have not yet established an end-to-end validated workflow. Interaction energy is not binding free energy; structure verification is not synthetic feasibility. Matched groove-directed work also retained negative results. Cellular folding, selective binding and functional effect each need their own test.
G4RNA screener and G4mer already provide learned, motif-independent formation analysis. G4mer also addresses subtypes and sequence variants.
| Question | Familiar approach | BioTwin | Why it matters |
|---|---|---|---|
| Will an rG4 form? | Sequence models prioritize likely structures and can assess variant effects. | Provides a formation route within a wider structural and design investigation. | Formation is a starting decision; no contemporary matched superiority over these models is claimed. |
| What could confer selectivity? | Structural analysis and docking examine candidate interactions. | Names feasibility, topology/shape and groove-direction operations for target/off-target comparisons. | A difference can become a substituent hypothesis with a concrete counterscreen. |
| What happens if the design fails? | A medicinal-chemistry workflow can revise the series or mechanism. | Includes candidate assembly and routes for considering alternative architectures or modalities. | A failed design can revise the intervention strategy while retaining the reason it failed. |
The end-to-end design chain remains a research proposition with stage-specific evidence. A formation result does not validate the later ligand-design operations.